## STE: STERIS plc (Ireland) - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.5% below STRENGTH zone (4.0-10.0%); PEG 1.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($241.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. STERIS (NYSE:STE) - Stock Analysis**
- Source: Simply Wall Street | 20251211T150824 | Somewhat-Bullish | Relevance: 100%
- This analysis of STERIS (NYSE:STE) highlights its current valuation, future growth prospects, and past performance. The company is trading 12.2% below its estimated fair value, with earnings projected to grow by 11.07% annually. STERIS benefits from secular demand trends in healthcare, facility expansion, and a robust portfolio of infection prevention products and services.

**2. Neuberger Berman Group LLC Has $4.66 Million Stock Holdings in STERIS plc $STE**
- Source: MarketBeat | 20251215T115851 | Somewhat-Bullish | Relevance: 100%
- Neuberger Berman Group LLC significantly increased its stake in STERIS plc (NYSE:STE) by 64.7% in Q2, bringing its total holdings to $4.66 million. Other institutional investors also adjusted their positions, and 94.69% of STERIS stock is now institutionally owned. The company recently reported strong earnings, issued a dividend, and saw insider selling activity, while analysts maintain a "Moderate Buy" rating with a consensus price target of $273.50.

**3. London Co. of Virginia Sells 35,896 Shares of STERIS plc $STE**
- Source: MarketBeat | 20251214T132325 | Somewhat-Bullish | Relevance: 100%
- London Co. of Virginia reduced its stake in STERIS plc (NYSE:STE) by selling 35,896 shares, bringing its total to 828,686 shares valued at $199.1 million. STERIS reported strong quarterly earnings, beating expectations with an EPS of $2.47, and has a consensus "Moderate Buy" rating with a $273.50 price target. Insider selling has also occurred, with VPs Renato Tamaro and Julia Madsen selling shares, collectively valued at $6.62 million from insider sales over the past 90 days.

**4. While shareholders of STERIS (NYSE:STE) are in the black over 3 years, those who bought a week ago aren't so fortunate**
- Source: Simply Wall Street | 20251213T140849 | Somewhat-Bullish | Relevance: 100%
- STERIS plc (NYSE:STE) shareholders have seen a 38% increase in share price over three years, though this is below the broader market return. The total shareholder return (TSR) including dividends was 42% over the same period, indicating dividends significantly boosted overall returns. While the stock has seen a recent dip, its long-term performance suggests underlying business momentum, making it potentially worthwhile for investors to delve deeper.

**5. While shareholders of STERIS (NYSE:STE) are in the black over 3 years, those who bought a week ago aren't so fortunate**
- Source: Simply Wall Street | 20251213T135716 | Somewhat-Bullish | Relevance: 100%
- STERIS plc shareholders have seen a 38% increase in share price over three years and a total shareholder return (TSR) of 42% including dividends, outperforming the market in the long term. However, recent buyers might be less fortunate, with the stock experiencing a 4.4% dip this past week. Despite this short-term fluctuation, the company has improved its profitability and shows positive momentum.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.73 elevated, pricing in significant growth expectations. Forward P/E 22.6x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.8B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.73 |
| Forward P/E | 22.6 |
| Current P/E | 24.7 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.2% to -3.5% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). AM_20 at -3.1% indicates price below own 20MA trend. Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). MACD histogram bearish (-1.83), momentum weakening. RSI neutral at 42. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.53% (CS: 13) | Weak |
| RSI_14 | 42.1 | Neutral |
| MACD Histogram | -1.83 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 1.055x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $251.79
- **Stop Loss:** $241.29 (4.2% risk)
- **Target:** $262.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 95
- **Position Value:** $23,920.05
- **Portfolio %:** 23.92%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*